Tag Archives: clinical trial
Pioneering drug discovery company Bridge Medicines launched to advance promising early technologies in major academic institutions through human proof of concept
The Tri-Institutional Therapeutics Discovery Institute, a partnership between Memorial Sloan Kettering Cancer Center, The Rockefeller University, Weill Cornell Medicine and Takeda, joins with Deerfield Management and Bay City Capital to create an accelerated path to innovative therapies to treat disease.
Antibody therapy may offer an alternative to standard HIV treatments, which require a strict regimen and can cause complications in the long-term. New results from a clinical trial show that the 3BNC117 antibody can significantly delay the virus from rebounding in patients taken off their current medications. More »
New therapy keeps HIV at bay without daily drug regimen, study says “Using antibodies against HIV could be part of a ‘kick and kill’ strategy, said study co-author Dr. Michel Nussenzweig — to kick the virus out of its … More »
Researchers are developing an antibody-based drug that may provide a better strategy for long-term control of HIV. New results from a clinical trial suggest that a single dose of a so-called broadly neutralizing antibody enables patients’ immune systems to better fight the virus. More »
In the first results to emerge from HIV patient trials of a new generation of so-called broadly neutralizing antibodies, Rockefeller University researchers have found the experimental therapy can dramatically reduce the amount of virus present in a patient’s blood. The work, reported this week in Nature, brings fresh optimism to the field of HIV immunotherapy and suggests new strategies for fighting or even preventing HIV infection. More »